Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Halozyme Therapeutics (NASDAQ: HALO) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Halozyme Therapeutics' (HALO) Price Target Raised to $21 at JMP June 4, 2015 8:23 AM Halozyme Therapeutics (HALO), AbbVie (ABBV) Enter Collaboration for ENHANZE CombinationsJune 3, 2015 8:31 AM Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVieJune 3, 2015 8:30 AM